Compare SPXC & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPXC | ICLR |
|---|---|---|
| Founded | 1912 | 1990 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 9.3B |
| IPO Year | 1994 | 2001 |
| Metric | SPXC | ICLR |
|---|---|---|
| Price | $233.39 | $149.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $245.56 | $178.62 |
| AVG Volume (30 Days) | 551.9K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.08 | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $2,265,100,000.00 | N/A |
| Revenue This Year | $16.07 | N/A |
| Revenue Next Year | $7.68 | N/A |
| P/E Ratio | $187.92 | ★ $12.91 |
| Revenue Growth | ★ 14.17 | N/A |
| 52 Week Low | $152.80 | $66.57 |
| 52 Week High | $246.68 | $211.00 |
| Indicator | SPXC | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 61.71 | 65.53 |
| Support Level | $186.02 | $99.11 |
| Resistance Level | $245.66 | $193.87 |
| Average True Range (ATR) | 9.97 | 7.85 |
| MACD | 1.33 | 1.43 |
| Stochastic Oscillator | 73.62 | 78.17 |
SPX Technologies Inc supplies engineered heating, ventilation, and air conditioning, or HVAC, products, as well as detection and measurement technologies and power equipment. The company operates through two reportable segments. The HVAC segment which generates the majority of the revenue for the company, designs, manufactures, installs, and services cooling products, as well as heating and ventilation products. The Detection and Measurement technologies segment designs, manufactures, and installs underground pipe and cable locators and inspection equipment, bus-fare collection systems, and others. Geographically, the company has its operations in the United States, Canada, China, the United Kingdom, and Others. It derives maximum revenue from United States.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.